Hyderabad (Telangana) [India], March 18: Kellton Tech Solutions Ltd. shares rallied almost 5% on Wednesday, halting a four-day losing streak with robust buying interest propelling the small-cap IT stock up as much as 4.92% to ₹17.25 apiece on the BSE. Trading activity intensified significantly, with approximately 8 lakh equity shares exchanged across stock exchanges, reflecting heightened investor enthusiasm.
The uptick comes on the heels of a broader market rebound, as benchmark indices Sensex and Nifty 50 each climbed over 0.5%, fostering a positive environment for small-cap performers like Kellton. This momentum follows the company’s recent announcement of a strategic partnership with FutureAge AI Labs to launch Zourney, an AI-first B2B travel platform unveiled in a regulatory filing on March 11.
Zourney is designed as an AI-native digital backbone for the travel industry, integrating intelligence across the entire value chain—from supplier onboarding and pricing intelligence to booking management, servicing workflows, and post-sales engagement. By creating a unified operating layer rather than overlaying automation on legacy systems, the platform enables smarter pricing decisions, real-time personalization, streamlined operations, and enhanced decision-making for travel partners, ultimately expanding inventory access and operational efficiency.
Despite the recent gains, Kellton Tech shares have faced headwinds, declining 14% over the past month, 8% year-to-date, 37% in six months, and 20% over the last year. On a longer horizon, the stock has shown resilience, rising 71% in three years and 23% over five years, underscoring potential recovery amid its focus on innovative AI-driven solutions in digital transformation.
Kellton Tech Solutions continues to position itself as a key player in emerging technologies, leveraging partnerships like Zourney to drive growth in competitive sectors such as travel, healthcare, retail, and financial services. Investors will watch closely for sustained momentum as the company capitalizes on its R&D investments and domain expertise.
Disclaimer: This article is for informational purposes only and does not constitute financial advice.
Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor